RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA

Core Insights - RemeGen Co., Ltd. has received clearance from the FDA for its IND application for phase II clinical trials of its bispecific antibody RC148 in the US [1][2] - RC148 targets PD-1 and VEGF and is developed using RemeGen's bispecific antibody technology platform [2] - The FDA clearance is a significant milestone that is expected to expedite the global development process of RC148 [2] Company Developments - RemeGen is currently conducting clinical trials of RC148 as both a monotherapy and in combination therapy for advanced solid tumors in China [2] - The successful IND application clearance marks an important step in RemeGen's strategy to expand its presence in the global oncology market [1][2]